Insilico Approach to Inhibit Over Expression of CaSm Gene to Arrest Over Expressed Human LSm1 Protein in Pancreatic Carcinoma Cell

Authors

  • Ansuman Mahato Department of Biotechnology, Garden City College, Bangalore, India

DOI:

https://doi.org/10.37591/(rrjobi).v1i3.367

Abstract

Small nuclear ribonucleoproteins (snRNPs) are particles that are found in the nucleus of eukaryotic cells. They consist of one RNA (snRNA) associated with one or more proteins. snRNPs are involved in a wide variety of functions including pre-mRNA splicing (e.g., U1, U2, U4–6, U11, U12, U4ATAC, U6ATAC snRNPs and transspliced leader RNPs), histone mRNA 39 end processing (U7 snRNP). The snRNA U6 (unlike U1, U2, U4 and U5) does not associate with the Sm proteins. In 1999 heteromer protein was identified that binds only to U6, and made up of seven proteins which are homologous to the Sm proteins. These proteins were denoted LSm (like Sm) proteins (LSm1, LSm2, LSm3, LSm4, LSm5, LSm6, and LSm7), LSm8 protein identified after that. The cancer associated
Sm-like protooncogene mRNA has been found to be overexpressed in the majority of pancreatic adenocarcinomas and is necessary for the transformed phenotype in pancreatic cancer cell lines. Human Lsm1, also called CaSm (cancer-associated Sm-like) was originally identified based on elevated expression in pancreatic cancer, in several cancer-derived cell lines as well as in metastatic tumors. CaSm is also required to maintain the transformed phenotype of prostate cancer cells and it can function as a oncogene in that over-expression of this gene. In this present study some of cancer drugs like S-adenosyl-L-Homocystein, S-adenosyl-L-Homoselenocystein, Adenosyl-ornithine and S-adenosylmethionine were tested through bioinformatics tools to check whether they could suppress the overexpression of LSm1 protein.

 

Keywords: Protooncogene, spliceosome, CaSm, human LSm, adenocarcinomas, ribonucleoproteins

Downloads

Published

2019-03-07

Issue

Vol. 1 No. 3 (2014)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.